Oncology and Hematology - Global Oncology Academy

433-448 of 743

Slowing Prostate Cancer Progression: The Role of Dietary Fat Modifications
Slowing Prostate Cancer Progression: The Role of Dietary Fat Modifications
On the Frontlines of Prostate Cancer
Slowing Prostate Cancer Progression: The Role of Dietary Fat Modifications
William Aronson, MD
- William Aronson, MD
Early-Stage Prostate Cancer Treatment: Examining Long-Term Complications
Early-Stage Prostate Cancer Treatment: Examining Long-Term Complications
On the Frontlines of Prostate Cancer
Early-Stage Prostate Cancer Treatment: Examining Long-Term Complications
Joseph Unger, PhD, MS
- Joseph Unger, PhD, MS
From Diagnosis to Treatment: Challenges in Glioblastoma Care
From Diagnosis to Treatment: Challenges in Glioblastoma Care
NeuroFrontiers
From Diagnosis to Treatment: Challenges in Glioblastoma Care
Lauren Schaff, MD
- Lauren Schaff, MD
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
MinuteCE®
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Fortunato Ciardiello, MD, PhD; Jenny Seligmann, MBChB, PhD
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
MinuteCE®
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Fortunato Ciardiello, MD, PhD; Jenny Seligmann, MBChB, PhD
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
From Guidelines to Practice: First-Line Treatment Choices in mCRC
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®
From Guidelines to Practice: First-Line Treatment Choices in mCRC
Fortunato Ciardiello, MD, PhD; Jenny Seligmann, MBChB, PhD
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
MinuteCE®
Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy
Jenny Seligmann, MBChB, PhD; Fortunato Ciardiello, MD, PhD
1.00 credit 10 episodes
- Jenny Seligmann, MBChB, PhD
- Fortunato Ciardiello, MD, PhD
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 credit 10 episodes
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Fortunato Ciardiello, MD, PhD; Jenny Seligmann, MBChB, PhD
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
MinuteCE®
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Fortunato Ciardiello, MD, PhD; Jenny Seligmann, MBChB, PhD
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
Project Oncology®
An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
Unresectable Hepatocellular Carcinoma Care: Investigating a Combination Therapy
Unresectable Hepatocellular Carcinoma Care: Investigating a Combination Therapy
Project Oncology®
Unresectable Hepatocellular Carcinoma Care: Investigating a Combination Therapy
Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist
Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist
Project Oncology®
Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist
Evaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial
Evaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial
Project Oncology®
Evaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial
Advancing Multiple Myeloma Treatment: The Role of Immunotherapy and Personalized Care
Advancing Multiple Myeloma Treatment: The Role of Immunotherapy and Personalized Care
Project Oncology®
Advancing Multiple Myeloma Treatment: The Role of Immunotherapy and Personalized Care
Shaji K. Kumar, MD
- Shaji K. Kumar, MD
The Impact of a Plant-Based Diet on Multiple Myeloma Prevention and Progression
The Impact of a Plant-Based Diet on Multiple Myeloma Prevention and Progression
Project Oncology®
The Impact of a Plant-Based Diet on Multiple Myeloma Prevention and Progression
Urvi A. Shah, MD, MS
- Urvi A. Shah, MD, MS
Establishing D-VRd Efficacy for Transplant-Ineligible Multiple Myeloma
Establishing D-VRd Efficacy for Transplant-Ineligible Multiple Myeloma
Project Oncology®
Establishing D-VRd Efficacy for Transplant-Ineligible Multiple Myeloma

28/11